Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 12/10/18 at 11:08am

Politics played a big role in pharma this week after Trump introduced legislation aimed at reducing the price of drugs. The effectiveness of trust-busting biosimilar bill in bring the medicines to market may be an interesting development over the coming year. Meanwhile the UK government came into question after researchers were denied visas.

Nevertheless Gilead’s CAR T therapy Yescarta got the go-ahead from NHS England while NICE recommended fizer’s Mylotarg combo thus offering hope for cancer patients in Britain. Meanwhile GSK cut 200 jobs in Ulverston while both MSD and Mundipharma completed multimillion pound deals.

Check out this week’s top ten most popular stories on Pharmafile.com!    

10. Celgene's Otezla impresses at Phase 3 in scalp psoriasis

Celgene has unveiled new Phase 3 data for Otezla (apremilast), its inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP), in the treatment of moderate to severe scalp psoriasis, with users showing a “highly statistically significant” increase in Scalp Physician’s Global Assessment (ScPGA) response, achieving its primary endpoint.

9. Janssen's Stelara shows promise across two dosages in ulcerative colitis

Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two dosage groups, with both reporting “statistically significant improvements” as measured on the Inflammatory Bowel Disease Questionnaire (IBDQ).

8. WHO voices concern over British immigration policies after researchers refused entry

The World Health Organization (WHO) has expressed concern over the UK’s immigration policies, after a number of academics were refused entry into Britain in order to attend the Global Symposium on Health Systems Research hosted in the coastal city of Liverpool.

7. NICE recommends Pfizer's Mylotarg combo in CD33-positive acute myeloid leukaemia

NICE has revealed its recommendation for Pfizer’s Mylotarg (gemtuzumab ozogamicin) to be used on the NHS in the treatment of previously untreated, de novo, CD33-positive acute myeloid leukaemia (AML).

6. US FDA approves HPV vaccine for men and women aged 27-45

The US Food and Drug Administration have approved the use of HPV vaccine Gardasil 9 for both men and woman between the ages of 27 and 45. Previously the vaccine had only been approved for those between the ages of 9 and 26.

5. MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department of Veteran Affairs.

4. NHS England approves Gilead's CAR T therapy Yescarta

Gilead’s CAR T therapy Yescarta is set to be made available on the NHS in England for adults with aggressive non-Hodgkin lymphoma, it was announced today.

3. Trump signs trust-busting biosimilar bill into law

President Donald J Trump has signed off a law which requires drugmakers and pharma firms to reveal the details of biosimilar deals to the US’ independent trust-busting agency the Federal Trade Commission (FTC).

2. Sackler-owned Mundipharma acquires biosimilar firm Cinfa Biotech

In a bid to strengthen their biosimilar portfolio, the Cambridge based pain management company Mundipharma has acquired biosimilar development firm Cinfa Biotech.

1. GSK to cut almost 200 jobs at UK site

GlaxoSmithKline has announced that it is to slash half of its workforce at its site in Ulverston, UK, as part of a move to cull cost-ineffective operations.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches